Theravance Biopharma earnings were $29.3M for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. The latest TBPH earnings report on Sep 30, 2025 announced Q3 2025 earnings of $3.6M, down 93.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, TBPH reported annual earnings of -$56.4M, with 2.2% growth.
TBPH past earnings growth
How has TBPH's earnings growth performed historically?
Theravance Biopharma Earnings Reports & History FAQ
What were Theravance Biopharma's earnings last quarter?
On TBPH's earnings call on Invalid Date, Theravance Biopharma (NASDAQ: TBPH) reported Q3 2025 earnings per share (EPS) of $0.07, up 126.92% year over year. Total TBPH earnings for the quarter were $3.62 million. In the same quarter last year, Theravance Biopharma's earnings per share (EPS) was -$0.26.
Is Theravance Biopharma profitable or losing money?
As of the last Theravance Biopharma earnings report, Theravance Biopharma is currently profitable. Theravance Biopharma's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $29.34 million, a 159.4% decrease year over year.
What was TBPH's earnings growth in the past year?
As of Theravance Biopharma's earnings date in Invalid Date, Theravance Biopharma's earnings has grown year over year. TBPH earnings in the past year totalled $29.34 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.